Form 4: Director Stephen Shoemaker Boosts ATNF Stake

180 Life Sciences Corp. Director Stephen H. Shoemaker acquired 919,761 non-qualified stock options at an exercise price of $2.92, aligning his interests with shareholders.

Summary

• Stephen H. Shoemaker, a Director of 180 Life Sciences Corp. (ATNF), reported changes in his beneficial ownership.
• He acquired 919,761 non-qualified stock options with an exercise price of $2.92 per share.
• These options were granted under the Issuer's 2025 Supplemental Option Plan.
• The options vested immediately but are exercisable only after the closing of the July 29, 2025, Securities Purchase Agreement transactions (which occurred on August 4, 2025) and upon stockholder approval of the 2025 Plan.
• If stockholder approval is not received by July 29, 2026, the options will be cancelled.
• Shoemaker also beneficially owns 132,439 shares of common stock directly.
• The options were issued in consideration for services rendered and agreed to be rendered as a director.

Sentiment

Score: 7

Explanation: The filing indicates a positive move to align director interests with shareholders through a substantial option grant. However, the conditional exercisability based on future stockholder approval introduces a degree of uncertainty, preventing a higher score.

Positives

• Director Stephen H. Shoemaker acquired a significant number of non-qualified stock options (919,761), aligning his interests with the company's performance and shareholder value.
• The options vested immediately, indicating a strong commitment from the company.
• The acquisition was in consideration for services as a director, reinforcing management's dedication.

Negatives

• The exercisability of the 919,761 options is conditional upon stockholder approval of the 2025 Supplemental Option Plan.
• If stockholder approval is not obtained by July 29, 2026, the options will be cancelled, posing a risk to the director's incentive and potential future value.

Risks

• The 919,761 non-qualified stock options granted to Director Stephen H. Shoemaker are subject to cancellation if stockholder approval of the 2025 Supplemental Option Plan is not received prior to July 29, 2026.

Future Outlook

The future exercisability of the granted options is contingent on obtaining stockholder approval for the 2025 Supplemental Option Plan by July 29, 2026, which will determine the long-term equity incentive for Director Shoemaker.

Management Comments

• The options were granted under the 2025 Supplemental Option Plan of the Issuer.
• The options vested immediately, but were not exercisable until or unless the closing of the transactions contemplated by the July 29, 2025, Securities Purchase Agreement between the Issuer and the purchasers set forth therein occurred, which closing date was August 4, 2025.
• Separately, the options are not exercisable until stockholder approval of the 2025 Plan is received. If stockholder approval is not received prior to July 29, 2026, the options will be cancelled.
• Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

Industry Context

This filing reflects a standard practice in the biotechnology and pharmaceutical industry where directors and key personnel are compensated with equity incentives, such as stock options, to align their long-term interests with the company's success and shareholder value. Such grants are common for companies like 180 Life Sciences Corp. (ATNF) which often rely on attracting and retaining talent through equity participation.

Comparison to Industry Standards

• The grant of 919,761 non-qualified stock options to a director, with an exercise price of $2.92, is a significant equity incentive.
• While specific comparable grants vary widely based on company size, stage, and market capitalization, this level of option grant is substantial for a director, particularly when considering the company's current market valuation.
• For instance, similar early-stage biotech companies might offer comparable equity packages to attract and retain experienced board members, though the specific terms and conditions, such as immediate vesting with conditional exercisability, can differ.
• Companies like smaller biotechs such as Athersys, Inc. (ATHX) or Sorrento Therapeutics, Inc. (SRNEQ) in their earlier stages have historically used substantial option grants to incentivize directors, though the specific value and conditions would need direct comparison to their respective filings.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director interests with shareholder value, contingent on the approval of the 2025 Supplemental Option Plan.
• Management/Directors: Stephen H. Shoemaker receives a significant equity incentive, motivating his continued service and performance.

Next Steps

• 180 Life Sciences Corp. needs to obtain stockholder approval for the 2025 Supplemental Option Plan.
• If stockholder approval is not received by July 29, 2026, the granted options will be cancelled.

Key Dates

Keywords

180 Life Sciences Corp., ATNF, Stephen H. Shoemaker, SEC Form 4, Beneficial Ownership, Stock Options, Director Compensation, Equity Incentive, Corporate Governance, Biotechnology, Pharmaceuticals